78 related articles for article (PubMed ID: 37073657)
1. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras.
Hamilton G; Stickler S; Rath B
Curr Pharm Des; 2023; 29(22):1741-1746. PubMed ID: 37073657
[TBL] [Abstract][Full Text] [Related]
2. Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W
Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo.
Pang X; Cui D; Lv B; Wang CY
J Med Chem; 2024 Jan; 67(2):1563-1579. PubMed ID: 38206836
[TBL] [Abstract][Full Text] [Related]
4. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Sudhakar N; Yan L; Qiryaqos F; Engstrom LD; Laguer J; Calinisan A; Hebbert A; Waters L; Moya K; Bowcut V; Vegar L; Ketcham JM; Ivetac A; Smith CR; Lawson JD; Rahbaek L; Clarine J; Nguyen N; Saechao B; Parker C; Elliott AJ; Vanderpool D; He L; Hover LD; Fernandez-Banet J; Coma S; Pachter JA; Hallin J; Marx MA; Briere DM; Christensen JG; Olson P; Haling J; Khare S
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38641404
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506-Binding Protein 51 (FKBP51).
Geiger TM; Walz M; Meyners C; Kuehn A; Dreizler JK; Sugiarto WO; Maciel EVS; Zheng M; Lermyte F; Hausch F
Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202309706. PubMed ID: 37942685
[TBL] [Abstract][Full Text] [Related]
6. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Smith CR; Chen D; Christensen JG; Coulombe R; Féthière J; Gunn RJ; Hollander J; Jones B; Ketcham JM; Khare S; Kuehler J; Lawson JD; Marx MA; Olson P; Pearson KE; Ren C; Tsagris D; Ulaganathan T; Van't Veer I; Wang X; Ivetac A
J Med Chem; 2024 Jan; 67(1):774-781. PubMed ID: 38156904
[TBL] [Abstract][Full Text] [Related]
8. One-Pot Synthesis of Cereblon Proteolysis Targeting Chimeras via Photoinduced C(sp
Arndt CM; Bitai J; Brunner J; Opatz T; Martinelli P; Gollner A; Sokol KR; Krumb M
J Med Chem; 2023 Dec; 66(24):16939-16952. PubMed ID: 38096359
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor.
Wang K; Zhou Z; Ma X; Xu J; Xu W; Zhou G; Zhou C; Li H; Zheng M; Zhang S; Xu T
Bioorg Med Chem Lett; 2024 May; 107():129780. PubMed ID: 38714262
[TBL] [Abstract][Full Text] [Related]
10. Combined KRAS
Thatikonda V; Lu H; Jurado S; Kostyrko K; Bristow CA; Bosch K; Feng N; Gao S; Gerlach D; Gmachl M; Lieb S; Jeschko A; Machado AA; Marszalek ED; Mahendra M; Jaeger PA; Sorokin A; Strauss S; Trapani F; Kopetz S; Vellano CP; Petronczki M; Kraut N; Heffernan TP; Marszalek JR; Pearson M; Waizenegger I; Hofmann MH
bioRxiv; 2023 Jan; ():. PubMed ID: 36747713
[TBL] [Abstract][Full Text] [Related]
11. Structurally Specific Z-DNA Proteolysis Targeting Chimera Enables Targeted Degradation of Adenosine Deaminase Acting on RNA 1.
Wang Z; Zhang D; Qiu X; Inuzuka H; Xiong Y; Liu J; Chen L; Chen H; Xie L; Kaniskan HÜ; Chen X; Jin J; Wei W
J Am Chem Soc; 2024 Mar; 146(11):7584-7593. PubMed ID: 38469801
[TBL] [Abstract][Full Text] [Related]
12. Progress in the controllability technology of PROTAC.
He X; Weng Z; Zou Y
Eur J Med Chem; 2024 Feb; 265():116096. PubMed ID: 38160619
[TBL] [Abstract][Full Text] [Related]
13. Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.
Begovich K; Schoolmeesters A; Rajapakse N; Martinez-Terroba E; Kumar M; Shakya A; Lai C; Greene S; Whitefield B; Okano A; Mali V; Huang S; Chourasia AH; Fung L
Mol Cancer Ther; 2024 Apr; 23(4):407-420. PubMed ID: 38224565
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis-targeting chimeras targeting epigenetic modulators: a promising strategy for oral cancer therapy.
Jayaseelan VP; Loganathan K; Pandi A; Ramasubramanian A; Kannan B; Arumugam P
Epigenomics; 2023 Dec; 15(23):1233-1236. PubMed ID: 37990892
[No Abstract] [Full Text] [Related]
15. Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery.
Wu J; Li X; Wu C; Wang Y; Zhang J
Eur J Med Chem; 2024 Mar; 268():116282. PubMed ID: 38430853
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells.
Plangger A; Rath B; Hochmair M; Funovics M; Hamilton G
Transl Oncol; 2021 Dec; 14(12):101230. PubMed ID: 34598083
[TBL] [Abstract][Full Text] [Related]
17. Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS-SOS1 Interface.
Ikram S; Sayyah E; Durdagi S
Chembiochem; 2024 Apr; ():e202400008. PubMed ID: 38622060
[TBL] [Abstract][Full Text] [Related]
18. Studying early structural changes in SOS1 mediated KRAS activation mechanism.
Bhadhadhara K; Jani V; Koulgi S; Sonavane U; Joshi R
Curr Res Struct Biol; 2024; 7():100115. PubMed ID: 38188543
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel SOS1 inhibitors using machine learning.
Duo L; Chen Y; Liu Q; Ma Z; Farjudian A; Ho WY; Low SS; Ren J; Hirst JD; Xie H; Tang B
RSC Med Chem; 2024 Apr; 15(4):1392-1403. PubMed ID: 38665844
[TBL] [Abstract][Full Text] [Related]
20. Annual review of PROTAC degraders as anticancer agents in 2022.
Wang X; Qin ZL; Li N; Jia MQ; Liu QG; Bai YR; Song J; Yuan S; Zhang SY
Eur J Med Chem; 2024 Mar; 267():116166. PubMed ID: 38281455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
